Nervous system neoplasm
| Nervous system neoplasm | |
|---|---|
| Specialty | Neurosurgery, oncology |
Nervous System Neoplasms
[edit]
A nervous system neoplasm is a tumor that arises within the nervous system, which includes both the central nervous system (CNS) and the peripheral nervous system (PNS). These neoplasms can be classified as primary or secondary[1][2]. Primary nervous system neoplasms include various types of brain and spinal cord tumors, such as gliomas, meningiomas, and schwannomas. Nervous system neoplasms can exhibit a wide range of behaviors, from benign to malignant[1]. Treatment and prognosis depend on factors such as tumor type, location, and molecular characteristics[1]. Although primary nervous system neoplasms are relatively rare, secondary (metastatic) tumors are more common in adults[2].
Classification
[edit]Nervous system neoplasms are classified into three broad categories based on their origin: primary CNS tumors, primary PNS tumors, and secondary (metastatic) CNS tumors[1][2].
Primary CNS tumors originate within the brain or spinal cord. They can be benign (non-cancerous) or malignant (cancerous). Some common types of primary CNS tumors include:
- Gliomas: Tumors arising from glial cells, which support and protect neurons. Subtypes include astrocytomas, oligodendrogliomas, and glioblastomas[2].
- Meningiomas: Tumors that develop in the meninges, the protective membranes covering the brain and spinal cord. These are typically benign and more common in adults[4].
- Medulloblastomas: Malignant tumors that commonly occur in the cerebellum, most often in children[4].
- Ependymomas: Tumors that arise from the ependymal cells lining the ventricles of the brain and the central canal of the spinal cord[4].
Primary PNS Tumors
[edit]Primary PNS tumors originate in the peripheral nerves and nerve sheaths. These tumors are often benign but can sometimes be malignant. Common types of primary PNS tumors include:
- Schwannomas: Tumors arising from Schwann cells, which produce the myelin sheath surrounding peripheral nerves. A common subtype is the vestibular schwannoma (acoustic neuroma)[5].
- Neurofibromas: Benign tumors that grow on nerves, commonly associated with neurofibromatosis type 1 (NF1)[2].
- Malignant Peripheral Nerve Sheath Tumors (MPNST): Rare but aggressive cancers that arise from peripheral nerves or nerve sheath cells[6].
Secondary (Metastatic) CNS Tumors
[edit]Secondary CNS tumors, or metastatic tumors, occur when cancer cells spread to the brain or spinal cord from a primary tumor in another part of the body. These tumors are more common than primary CNS tumors in adults and often originate from cancers such as: [7]
- Lung Cancer
- Breast Cancer
- Melanoma
- Kidney Cancer
- Colon Cancer
Diagnosis
[edit]Clinical Evaluation
[edit]Diagnosing nervous system neoplasms typically begins with a comprehensive medical history and neurological examination. The goal of the evaluation is to identify any neurological changes that may suggest the presence of a tumor. The assessment considers factors such as the nature, progression, and duration of the patient's symptoms, as well as any relevant medical history.[8]
Because nervous system neoplasms can have a wide range of presentations, clinical evaluation is often followed by neuroimaging to confirm or rule out the presence of a tumor. Further testing, such as a biopsy, may be necessary to determine the tumor type and grade.[2][8]
Advances in Diagnostic Methods
[edit]Advances in imaging technologies, molecular diagnostics, and targeted therapies have significantly improved the accuracy of diagnosis and the effectiveness of treatment.[9][10][3].
Neuroimaging
[edit]Magnetic Resonance Imaging (MRI) with contrast is the primary imaging modality for diagnosing brain and spinal cord tumors due to its high-resolution visualization of soft tissues. MRI helps identify the tumor's location, size, and potential impact on surrounding structures. In emergency situations or when MRI is contraindicated, Computed Tomography (CT) is used as an alternative.[11]
Advanced Imaging Techniques
[edit]Additional imaging techniques can provide further insights when standard MRI or CT findings are inconclusive: [2]
- Magnetic Resonance Spectroscopy (MRS) analyzes the chemical composition of brain tissue to differentiate tumors from non-neoplastic conditions such as infections or demyelinating diseases.
- Positron Emission Tomography (PET) assesses metabolic activity and can distinguish between tumor recurrence and treatment-related changes.
- Diffusion Tensor Imaging (DTI) maps white matter tracts and helps plan surgeries to avoid critical brain regions.
Biopsy and Pathological Analysis
[edit]A definitive diagnosis often requires a tissue biopsy. The biopsy can be performed through an open surgical procedure or a minimally invasive stereotactic technique.[12] Histopathological examination determines the tumor type, grade, and molecular characteristics, which are critical for guiding treatment decisions.[13]
Advances in molecular diagnostics allow for the identification of genetic and molecular markers, improving the precision of tumor classification and enabling targeted therapies.[14]
Lumbar Puncture
[edit]In some cases, a lumbar puncture (spinal tap) may be performed to analyze cerebrospinal fluid (CSF). This can help detect tumor cells, especially in cases of suspected leptomeningeal metastasis or primary CNS lymphoma. The presence of tumor markers or abnormal cells in the CSF can provide diagnostic information that complements imaging and biopsy findings.[2]
Epidemiology
[edit]Nervous system neoplasms vary in incidence and type based on factors such as age, tumor origin, and malignancy.
Gliomas
[edit]Gliomas, tumors originating from glial cells, are the most common malignant primary brain tumors, accounting for approximately 81% of malignant brain tumors and 26% of all brain and CNS tumors[15] . Gliomas arise from different types of glial cells:
- Astrocytes – resulting in astrocytomas
- Oligodendrocytes – resulting in oligodendrogliomas
- Ependymal cells – resulting in ependymomas
Glioblastomas, the most aggressive form of glioma, make up approximately 47.7% of all gliomas[15]. The incidence rate of glioblastomas is 3.23 per 100,000 people[9]. The 5-year survival rate for glioblastoma is only 6.8%[9].
Meningiomas
[edit]Meningiomas, which develop in the meninges, are common primary brain tumors, representing approximately 37% of all brain tumors[15]. The incidence rate for meningiomas is 9.51 per 100,000 people[9]. Unlike gliomas, more than 98% of meningiomas are nonmalignant[15]. The 5-year survival rate for nonmalignant meningiomas is approximately 91%[9].
Pediatric Brain Tumors
[edit]In children aged 0–14 years, the most common brain tumors are: [15]
- Pilocytic astrocytomas – 17.5%
- Embryonal tumors – 15.7%
- Malignant gliomas – 25.7%
The overall incidence rate of brain tumors in children is 6.2 per 100,000[9].
The distribution and behavior of nervous system neoplasms differ significantly between adults and children. Gliomas are more frequent and aggressive in adults, while certain benign tumors like pilocytic astrocytomas are more common in children. Notably, adults are more likely to develop secondary (metastatic) tumors that spread to the nervous system from cancers originating in other parts of the body[1].
Demographic Trends
[edit]Brain tumor incidence varies by age, sex, and race. Overall, brain and CNS tumors are more common in females due to the higher prevalence of meningiomas[9]. However, malignant tumors like glioblastomas are more frequently diagnosed in males[9].
References
[edit]- ^ a b c d e "Adult Central Nervous System Tumors Treatment (PDQ®)". National Cancer Institute. 2024-03-29. Retrieved 2024-06-07.
- ^ a b c d e f g h "Brain and Spinal Cord Tumors". National Institute of Neurological Disorders and Stroke. Retrieved 2024-06-07.
- ^ a b Louis, David N.; Perry, Arie; Wesseling, Petra; Brat, Daniel J.; Ellison, David W.; Figarella-Branger, Dominique; Hawkins, Cynthia; Ng, Ho-Keung; Pfister, Stefan M.; Reifenberger, Guido; Soerensen, Neil; Von Deimling, Andreas (2021). "The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary". Neuro-Oncology. 23 (8): 1231–1251. doi:10.1093/neuonc/noab106. PMC 8328013. PMID 33408488.
- ^ a b c "Rare Brain and Spine Tumors". NCI. 17 September 2018. Retrieved 2024-06-08.
- ^ "Vestibular Schwannoma (Acoustic Neuroma) and Neurofibromatosis". National Institute on Deafness and Other Communication Disorders. 6 March 2017. Retrieved 2024-06-07.
- ^ "Malignant Peripheral Nerve Sheath Tumor (MPNST)". NCI. 22 July 2020. Retrieved 2024-06-08.
- ^ Brenner, Alex W.; Patel, Akash J. (2022). "Review of Current Principles of the Diagnosis and Management of Brain Metastases". Frontiers in Oncology. 12. doi:10.1155/2022/4635806. PMC 9171239. PMID 35720039.
- ^ a b Thomas, Reena P.; Iv, Michael (2024). "Clinical Features of Brain Tumors and Complications of Their Treatment". In Bradley, W. J. (ed.). Neurology: Principles and Practice (3rd ed.). Elsevier. ISBN 9780323642613.
- ^ a b c d e f g h Ostrom, Quinn T.; Cioffi, George; Greenlee, Rebecca T.; Kruchko, Clair; Barnholtz-Sloan, Jill S. (2021). "CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019". Neuro-Oncology. 23 (12): 1961–1985. doi:10.1093/neuonc/noab200. PMC 9533228. PMID 36196752.
- ^ "Brain and Spinal Cord Tumor Research". National Cancer Institute. 12 July 2022. Retrieved 2024-06-07.
- ^ Wong, Eric T.; Wu, Julian K. (2023-10-19). Wen, Patrick Y.; Eichler, April F. (eds.). "Overview of the Clinical Features and Diagnosis of Brain Tumors in Adults". UpToDate. Retrieved 2024-06-08.
- ^ Jackson, R.J.; Fuller, G.N.; Abi-Said, D.; Lang, F.F.; Gokaslan, Z.L.; Shi, W.M.; Wildrick, D.M.; Sawaya, R. (2001). "Limitations of Stereotactic Biopsy in the Initial Management of Gliomas". Neuro-Oncology. 3 (3): 193–200. doi:10.1093/neuonc/3.3.193. PMC 1920616. PMID 11465400.
- ^ Ballester, Leomar Y.; Huse, Jason T. (2024). "Pathology and Molecular Genetics". In Bradley, W. J. (ed.). Bradley and Daroff's Neurology in Clinical Practice (8th ed.). Elsevier. pp. 1076–1098.e2. ISBN 9780323642613.
- ^ Pan, Chong; Diplas, Basilios H.; Chen, Xiaonan; Geng, Ying; Sheng, Hongtao; Liang, Hao; Tang, Kening; Wu, Yang; Zhang, Peng; Chen, Long; Yang, Hai; Xiao, Jian; Yan, Huajun; Zhou, Wei; Zhang, Junchao; Wang, Jun; Yan, Hui (2019). "Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA". Acta Neuropathologica. 137 (2): 297–306. doi:10.1007/s00401-018-1936-6. PMC 7523750. PMID 30460397.
- ^ a b c d e Michaud, Dominique S. (2024). "Epidemiology of Brain Tumors". In Bradley, W. J. (ed.). Neurology: Principles and Practice (3rd ed.). Elsevier. ISBN 9780323642613.
External links
[edit]_(14784117803).jpg){kind=small} | This article about a medical condition affecting the nervous system is a stub. You can help Wikipedia by expanding it. |
 | This article about a neoplasm is a stub. You can help Wikipedia by expanding it. |